Issues related to non-opioid alternatives reimbursement. Coverage decisions related to anti nausea treatments. Federal non-opioid directive legislation
2026 · 1st Quarter (Jan 1 - Mar 31)
HERON THERAPEUTICS, INC.
Filed by FARRAGUT PARTNERS LLP.
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 20, 2026
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- FARRAGUT PARTNERS LLP
- Client
- HERON THERAPEUTICS, INC.
- Filing UUID
- abc12f88-5529-4f86-9683-8081eeef7d56
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to non-opioid alternatives reimbursement. Coverage decisions related to anti nausea treatments. Federal non-opioid directive legislation
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.